ClinicalTrials.gg
RecruitingNCT07363148Updated Sep 30, 2026

A Clinical Trial to Investigate the Safety and Efficacy of MB-1 on Metabolic Health in Overweight and Obese Adults

An interventional study of MB-1 and Placebo in Obese, Overweight Adults and Obese Adults, sponsored by Arrae. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Arrae · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Sep 30, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 574 studies in Obesity with a site in Canada — 101 open to participants now, 150 under way, 46 of them phase 3. Obesity · Canada.

Planned enrollment
179th of 479
120 · median 73
Started
2026
with 52 others
No phase
280 of 574
34 open now
Primary completion
2027-02
later than 65 of 149 live
Registered
525th of 574
by date

Among the 574 studies in Obesity with a site in Canada, this one is the 179th largest by planned enrollment of the 479 interventional ones that give a count, is one of 53 that started in 2026, is one of 280 with no phase, reaches primary completion later than 65 of the 149 other live ones, and was the 525th registered.

Obesity

11,536 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

101 of the 574 studies in Obesity with a site in Canada are open now. Recruiting first, the newest first:

95 more — sign in →

All 101 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 574 studies in Obesity with a site in Canada, or all of them as a file.
02

Study summary

The goal of this clinical trial is to investigate the safety and efficacy of MB-1 on metabolic health in overweight and obese adults. The main question it aims to answer is:

What is the difference in change in body weight from baseline at Day 84 between MB-1 and placebo?

Participants will be provided MB-1 or placebo and be assessed for anthropometric measurements, blood pressure, heart rate, and asked to complete appetite and satiety questionnaires and undergo a DEXA scan.

03

Conditions studied

  • Obese
  • Overweight Adults
  • Obese Adults
  • Body Weight Control
  • BMI

Keywords

  • Arrae
  • MB-1
  • Obesity
  • Overweight
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males \& females aged 18-50 years, inclusive
  2. of 25.0 to ≤ 34.9 kg/m²
  3. Females not of , defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been for at least 1 year prior to screening Or,

    Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically-approved method of for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:

    • Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
    • Double-barrier method
    • Intrauterine devices
    • Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)
    • Vasectomy of partner at least 6 months prior to screening
    • Abstinence and agrees to use contraception if planning on becoming sexually active during the study
  4. Stable body weight defined as a \<5% change in body weight in the three months prior to baseline as assessed by the QI
  5. Abdominal obesity: Waist circumference of > 94 cm (37 inches) in men and > 80 cm (31.5 inches) in women
  6. Willingness to complete questionnaires, records and diaries associated with the study and to complete all clinic visits
  7. Agrees to maintain current lifestyle habits (diet, medications, supplements, and sleep) as much as possible throughout the study
  8. Provided voluntary, written, to participate in the study
  9. Healthy as determined by medical history as assessed by Qualified Investigator (QI)

Exclusion criteria

Exclusion Criteria:

  1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
  2. Allergy, sensitivity, or intolerance preventing consumption of the product or placebo ingredients
  3. Gastric bypass surgery or other surgeries to induce weight loss
  4. Metal implants or other physical characteristics/limitations that may affect DEXA scan results as assessed by the QI
  5. Currently taking weight loss medications or participated in a weight loss program within the past three months as assessed by the QI
  6. Current or history of eating disorders as assessed by the QI
  7. Unstable metabolic disease or chronic diseases as assessed by the QI
  8. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI
  9. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
  10. Participants residing in the same household as another study participant unless they are enrolled consecutively (e.g. not actively enrolled at the same time)
  11. Type I or Type II diabetes
  12. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis
  13. History of or current diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months
  14. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
  15. Self reported confirmation of glaucoma
  16. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI
  17. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable
  18. Individuals with an disease or are immune compromised as assessed by the QI
  19. Self-reported confirmation of a -, - and/or C-positive diagnosis as assessed by the QI
  20. Self-reported confirmation of blood/bleeding disorders as assessed by the QI
  21. Chronic use of cannabinoid products (>2 times/week) as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period
  22. Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period
  23. Alcohol intake average of >2 standard drinks per day as assessed by the QI
  24. Alcohol or drug abuse within the last 12 months
  25. Current use of prescribed and/or over-the-counter (OTC) medications, supplements, and/or consumption of food/drinks that may impact the efficacy and/or safety of the investigational product (Section 7.3)
  26. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit
  27. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI
  28. Individuals who are unable to give
  29. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    MB-1

    MB-1 contains African mango seed (Irvingia Gabonensis), Cissus leaf (Cissus quadrangularis) extract, Grains of Paradise (Aframomum melegueta), Bifidobacterium Lactis (B. lactis) B420, Green tea extract (standardized to 92 ± 2.5 % caffeine), Green tea extract (Camellia sinensis), Vitamin B6, and Chromium Picolinate.

    Dietary Supplement: MB-1

  • Experimental
    Placebo

    Placebo contains white rice flour

    Other: Placebo

Interventions

  • Dietary supplementMB-1

    Participants will be instructed to take two capsules every morning with a meal for the duration of the study starting on Day 1 until the day prior to their end of study visit.

  • OtherPlacebo

    Participants will be instructed to take two capsules every morning with a meal for the duration of the study starting on Day 1 until the day prior to their end of study visit.

06

What researchers measure

Primary outcomes

  1. The difference in change in body weight between MB-1 and placebo

    The difference in change in body weight from baseline at Day 84 between MB-1 and placebo

    Time frame: Day 0 to 84

Secondary outcomes

  1. The difference in change in body weight between MB-1 and placebo

    The difference in change in body weight from baseline at Day 42 between MB-1 and placebo

    Time frame: Day 0 to 42

  2. The difference in change in anthropometric measures (waist and hip circumference) between MB-1 and placebo

    The difference in change in anthropometric measures (waist and hip circumference) from baseline at Days 42 between MB-1 and placebo

    Time frame: Day 0 to 42

  3. The difference in change in anthropometric measures (waist and hip circumference) between MB-1 and placebo

    The difference in change in anthropometric measures (waist and hip circumference) from baseline at Day 84 between MB-1 and placebo

    Time frame: Day 0 to 84

  4. The difference in change in body composition (fat and muscle mass) between MB-1 and placebo as assessed by Dual-Energy X-Ray Absorption (DEXA)

    The difference in change in body composition (fat and muscle mass) from baseline at Day 84 between MB-1 and placebo as assessed by Dual-Energy X-Ray Absorption (DEXA)

    Time frame: Day 0 to 84

  5. The difference in change in fasting blood glucose between MB-1 and placebo as assessed by fasting blood glucose

    The difference in change in fasting blood glucose from baseline at Day 84 between MB-1 and placebo as assessed by fasting blood glucose

    Time frame: Day 0 to 84

  6. The difference in change in lipid profile between MB-1 and placebo

    The difference in change in lipid profile: total cholesterol (TC) between MB-1 and placebo

    Time frame: Day 0 to 84

  7. The difference in change in lipid profile between MB-1 and placebo

    The difference in change in lipid profile: low-density lipoprotein cholesterol (LDL-C between MB-1 and placebo

    Time frame: Day 0 to 84

  8. The difference in change in lipid profile between MB-1 and placebo

    The difference in change in lipid profile: high-density lipoprotein cholesterol (HDL-C) between MB-1 and placebo

    Time frame: Day 0 to 84

  9. The difference in change in lipid profile between MB-1 and placebo

    The difference in change in lipid profile: non-HDL-C between MB-1 and placebo

    Time frame: Day 0 to 84

  10. The difference in change in lipid profile between MB-1 and placebo

    The difference in change in lipid profile: triglycerides (TG) between MB-1 and placebo

    Time frame: Day 0 to 84

  11. The difference in change in lipid profile between MB-1 and placebo

    The difference in change in lipid profile: TG/HDL-C, TC/HDL-C and LDL-C/HDL-C between MB-1 and placebo

    Time frame: Day 0 to 84

  12. The difference in change in ratings of appetite, satiety, and cravings between MB-1 and placebo as assessed by the weekly Appetite, Satiety and Cravings Likert scales.

    The difference in change in ratings of appetite, satiety, and cravings between MB-1 and placebo as assessed by the weekly Appetite, Satiety and Cravings Likert scales.

    Time frame: Day 0 to 84

  13. The difference in change in ratings of energy between MB-1 and placebo as assessed by the weekly Energy Likert scale.

    The difference in change in ratings of energy from baseline at Day 84 between MB-1 and placebo as assessed by the weekly Energy Likert scale.

    Time frame: Day 0 to 84

Other outcomes

  1. Incidence of post-emergent adverse events (AE)

    Incidence of post-emergent adverse events (AE)

    Time frame: Day 0 to 84

  2. Clinically relevant changes in heart rate (HR) after supplementation

    Clinically relevant changes in heart rate (HR) after supplementation

    Time frame: Day 0 to 84

  3. Clinically relevant changes in blood pressure (BP) after supplementation

    Clinically relevant changes in blood pressure (BP) after supplementation

    Time frame: Day 0 to 84

  4. Clinically relevant changes in liver function

    Clinically relevant changes in liver function.

    Time frame: Day 0 to 84

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Feb 2027, 6 months after the start.

Of 163 industry-sponsored interventional studies with no phase under Obesity, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 27. This study's planned 6 months is below that.

Counting every sponsor, half of 3,853 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Jan 2027 → Feb 2027 and completion Jan 2027 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2026
First posted
Jan 23, 2026
StartActual
Aug 5, 2026
Primary completionEst.
Feb 2027was Jan 2027
CompletionEst.
Feb 2027was Jan 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 30, 2026
Sites
KGK Science Inc. is now Recruiting
Sep 30, 2026
Primary completion
Jan 2027→Feb 2027
Sep 30, 2026
Study completion
Jan 2027→Feb 2027
Sep 30, 2026
Contact
Study contact changed: m•••@kgkscience.com · •••9094→e•••@kgkscience.com · •••4248. See the current contact
Sep 30, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • KGK Science Inc. · London, CanadaContact m•••@kgkscience.com · •••9094→e•••@kgkscience.com · •••4248
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Not yet recruiting→Recruiting
    KGK Science Inc. is now Recruiting
    Primary completion Jan 2027→Feb 2027
    Study completion Jan 2027→Feb 2027
    Contact Study contact changed: m•••@kgkscience.com · •••9094→e•••@kgkscience.com · •••4248. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • KGK Science Inc. · London, CanadaContact m•••@kgkscience.com · •••9094→e•••@kgkscience.com · •••4248
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07363148
Lead sponsor
Arrae
Collaborators
KGK Science Inc.
Responsible party
Sponsor
First posted
Jan 23, 2026
Start date
Aug 5, 2026
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Erin Lewis, PhD
Contact
elewis@kgkscience.com
519-438-9374 x 248
David Crowley, MD
principal investigator · KGK Science Inc.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion